Arcutis Biotherapeutics Inc (ARQT) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

Total Cash From Operating Activities Chart for Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc (ARQT) operating cash flow for FY2025 was USD -5.6M. Arcutis Biotherapeutics Inc's operating cash flow moved from USD -3.8M in 2017 to USD -5.6M in 2025 over 8 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$3.92B
Implied Share Price
$31.20
Enterprise Value
$2.47B
Revenue (TTM)
$463.98M
EBITDA
$36.50M
Profit Margin
6.15%
Trailing P/E
141.82
Forward P/E
263.16
Price/Book (MRQ)
18.33
Price/Sales (TTM)
8.45
EV/EBITDA
-2.04
EV/Revenue
9.36
Dividend Yield
—
Book Value
$1.76
Free Cash Flow (FY2025)
-$6.31M
Free Cash Flow Yield
-0.16%

Snapshot as of 25th October 2026 — not point-in-time controlled, may lag the live market by a few days.